Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 7/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2366907 | 0.84 | HRH4 (0.48) | HRH4CHRNB2CHRNA4HTTHTR2C | |
| SCHEMBL902974 | 0.83 | CHRNB2 (0.54) | HRH4CHRNB2CHRNA4 | |
| SCHEMBL14335373 | 0.83 | HRH4 (0.47) | HRH4CHRNB2CHRNA4HTTHTR2C | |
| SCHEMBL898877 | 0.83 | CHRNB2 (0.50) | HRH4CHRNB2CHRNA4HTT | |
| Hydrochloric Acid SCHEMBL30903348 | 0.81 | CHRNB2 (0.49) | HRH4CHRNB2CHRNA4HTT | |
| SCHEMBL24970994 | 0.79 | ADRB1 (0.49) | CHRNB2CHRNA4HTR2CNCF1 | |
| SCHEMBL2418069 | 0.79 | EPHX2 (0.56) | HRH4CHRNB2CHRNA4HTTNCF1 | |
| SCHEMBL12694213 | 0.79 | CHRNB2 (0.43) | HRH4CHRNB2CHRNA4HTTHTR2C | |
| Hydrochloric Acid SCHEMBL30223019 | 0.78 | ADRB1 (0.48) | CHRNB2CHRNA4HTR2CNCF1 | |
| SCHEMBL903045 | 0.77 | ALDH1A1 (0.52) | CHRNB2CHRNA4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621920-A1 | NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | Bristol-Myers Squibb Company (US) | 2013-08-07 | — | — | EP | disclosed |
| CN-103209977-A | Novel piperazine analogs with substituted heteroaryl groups as broad-spectrum influenza antivirals | BRISTOL MYERS SQUIBB CO | 2013-07-17 | — | — | CN | disclosed |
| US-20120245176-A1 | NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-27 | — | — | US | disclosed |
| US-20120245176-A1 | NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-27 | — | — | US | disclosed |
| US-20120245176-A1 | NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-27 | — | — | US | disclosed |
| WO-2012044531-A1 | NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012044531-A1 | NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245176-A1 | NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | ZC3HAV1, ZC3HAV1L, BAZ2A | HRH4 60/4885CHRNB2 1589/4885CHRNA4 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.